SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND MITOCHONDRIAL FUNCTIONS: STATE OF THE ART

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced antidiabetic drugs with po-tent hypoglycemic effects. Recent evidence suggests that these drugs have extraglycemic impacts and are therefore able to provide additional benefits beyond glucose lowering. Mitochondrial dysfunction is a central facet of many disorders that negatively impacts many tissues and organs, especially in the setting of diabetes. Therefore, it would be hugely beneficial if an antidiabetic drug could also provide mitochondrial benefits to improve cellular function and reduce the risk of diabetic complications. In this review, we have surveyed the literature for possible mito-chondrial benefits of SGLT2is and we discuss the possible mechanisms involved.

Automated summary

SGLT2is, a class of newly introduced antidiabetic drugs, have potent hypoglycemic effects and may also provide additional non-glycemic benefits, including the improvement of mitochondrial function.